Lock In A Phenomenal Yield With Pfizer

Summary

• Pfizer's stock has declined by 50% over several years, yet it maintains a nearly 6% dividend yield, making it a valuable long-term investment.
• The company's quarterly performance includes $13.3 billion in revenue, $2.7 billion in R&D expenditures, and a $0.6 adjusted EPS, with respectable growth.
• Pfizer's oncology investments, including the $40 billion Seagen acquisition, show substantial YoY revenue growth and a robust pipeline of new drugs.
• Despite industry risks, Pfizer's strong cash flow, significant R&D spending, and ability to pay down debt make it an undervalued company with impressive shareholder returns.
• The Retirement Forum members get exclusive access to our real-world portfolio. See all our investments here »

carmengabriela

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.